Pfizer: One of the world's premier biopharmaceutical companies

Getting to Know Pfizer’s New Chief Medical Officer Aida Habtezion

Our People

Getting to Know Pfizer’s New Chief Medical Officer Aida Habtezion

Changing careers in the middle of a pandemic is no small endeavor. But when Aida Habtezion, M.D., learned about the opportunity to serve as Pfizer’s new Chief Medical Officer, she couldn’t pass it up.

Meet Aida

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

Our Science

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

The U.S. FDA authorization of the Pfizer-BioNTech COVID-19 vaccine for emergency use is a significant step forward in our fight against this pandemic.

Learn More

COVID-19 SCIENTIFIC RESOURCES

Our Science

COVID-19 SCIENTIFIC RESOURCES

Current information on our scientific progress to bring forward a safe and effective vaccine to help protect against the novel coronavirus.

More Here

In His Shoes (or Hiking Boots)

Our Health

In His Shoes (or Hiking Boots)

When it comes to making the world a better place for people living with hemophilia—a rare disease characterized by inadequate blood clotting—William Addison doesn’t just talk the talk.

Learn more about William

Search products

Search products, A–Z

Need help paying for Pfizer medicines?

Find a Trial

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

One Year Later: What We Have Learned

Your Health

One Year Later: What We Have Learned

Thoughts from our Chairman and CEO on a year defined by loss, learning and an approaching liberation.

VISIT OUR COVID-19 HUB

Our Science

VISIT OUR COVID-19 HUB

Sharing resources to stay safe and updates on our efforts we hope could bring an end to the global health crisis.

Learn More

Latest News

Myovant Sciences and Pfizer Announce First…

BASEL, Switzerland and NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 SERENE study evaluating the contraceptive efficacy of relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in healthy women ages 18-35 years who are at risk for pregnancy.